Compare Gartner Inc (IT) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gartner Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Gartner Inc trades at $197.19 (market cap $12.44B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Gartner Inc is far larger — about 12.8× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Gartner Inc is more actively traded (818,587 versus 4,325,710). Which is the better fit depends on your goals — on Pluang, investors hold Gartner Inc for 65 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| IT | MRVI | |
|---|---|---|
Market Cap | $12.44B | $972.90M |
Volume | 818,587 | 4,325,710 |
Sector | Technology | Health |
52-Week High | $258.17 | $9.00 |
52-Week Low | $125.68 | $2.83 |
Typical Hold Time | 65 Days | 0 Days |
Enterprise Value | $14.18B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gartner Inc. (IT) trades at $195.77, up 0.86% on the day, with a bullish technical signal and strong profitability metrics including a 69.63% gross margin and 113.58% ROE. Recent earnings beats and positive news flow around AI advisory demand support the stock, though net cash flow turned negative in 2025. The current price sits above the consensus target of $178.14, indicating potential overvaluation concerns among analysts.
Outlook remains positive due to robust contract value growth and AI-driven demand, but risks include volatile cash flows, high P/B ratio of 160.06, and a shareholder investigation. Investor sentiment is mixed with 55.55% hold ratings, suggesting cautious optimism amid execution risks and macroeconomic uncertainty.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
